Document is current
Any future updates will be listed below
-
Authors
Abdel Hamid, Marwa
Pammer, Lorenz M.
Oberparleiter, Silvia
Günther, Michael
Amann, Arno
Gruber, Rebecca A.
Mair, Anna
Nocera, Fabienne I.
Ormanns, Steffen
Zimmer, Kai
Gerner, Romana R.
Kocher, Florian
Vorbach, Samuel M.
Wolf, Dominik
Riedl, Jakob M.
Huemer, Florian
Seeber, Andreas
- License Information
-
More Information
Article History
Received: 5 December 2024
Accepted: 31 March 2025
First Online: 22 April 2025
Competing interests
: The authors declare that they have no personal relationships and no competing financial or academic conflicts of interest related to the submitted project, except for two authors who have declared relationships with pharmaceutical companies. These competing interests, detailed below, did not influence the results, interpretations, or conclusions of this review.FH: Honoraria: Lilly, Pierre Fabre, Amgen, Servier, Daiichi Sankyo, BMS, Merck, Sanofi, Roche, Janssen, PharmaMar, Astellas; Travel support: Servier, BMS, Roche, Merck, PharmaMar, Pfizer, Pierre Fabre, Sanofi, Daiichi Sankyo, Gilead; Stock and other ownership interests: Guardant Health, Natera, Revolution Medicines JR: Other interactions with: Amgen, BMS, MSD, Merck, Eli Lilly, Roche, Servier, Pierre Fabre; Research grants: Roche, Servier.
